Evidence map›Paper›PMID 42796494›Full record

ReviewMolecules (Basel, Switzerland)2026

Pentacyclic Triterpenoid Acids in the Treatment of Breast Cancer.

Natalia Jankowska, Rostyslav Dudchak, Magdalena Podolak, Marcin Cybulski, Elisabetta Esposito, Olga Michalak, Krzysztof Bielawski, Anna Bielawska, Agnieszka Gornowicz

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Natalia JankowskaDepartment of Biotechnology, Medical University of Bialystok, 1 Kilińskiego Str., 15-089 Białystok, Poland.ORCID 0009-0003-5804-1729
Rostyslav DudchakDepartment of Synthesis and Technology of Drugs, Medical University of Bialystok, 1 Kilińskiego Str., 15-089 Białystok, Poland.
Magdalena PodolakDepartment of Biotechnology, Medical University of Bialystok, 1 Kilińskiego Str., 15-089 Białystok, Poland.
Marcin CybulskiChemistry Section, Pharmacy, Cosmetic Chemistry and Biotechnology Research Group, Łukasiewicz Research Network-Industrial Chemistry Institute, 8 Rydygiera Str., 01-793 Warsaw, Poland.ORCID 0000-0002-4560-9317
Elisabetta EspositoDepartment of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, Via Fossato di Mortara, 19-44121 Ferrara, Italy.ORCID 0000-0002-8416-3629
Olga MichalakChemistry Section, Pharmacy, Cosmetic Chemistry and Biotechnology Research Group, Łukasiewicz Research Network-Industrial Chemistry Institute, 8 Rydygiera Str., 01-793 Warsaw, Poland.ORCID 0000-0002-1067-4223
Krzysztof BielawskiDepartment of Synthesis and Technology of Drugs, Medical University of Bialystok, 1 Kilińskiego Str., 15-089 Białystok, Poland.ORCID 0000-0003-3187-4205
Anna BielawskaDepartment of Biotechnology, Medical University of Bialystok, 1 Kilińskiego Str., 15-089 Białystok, Poland.
Agnieszka GornowiczDepartment of Biotechnology, Medical University of Bialystok, 1 Kilińskiego Str., 15-089 Białystok, Poland.ORCID 0000-0002-0945-7870

Funding

Medical University of Białystok B.SUB.26.270Narodowa Agencja Wymiany Akademickiej BPI/PST/2024/1/00047/U/00001
6 · The paper itself

Abstract

Despite increasing awareness about cancer, it still remains one of the biggest threats to human life. Breast cancer is among the most commonly diagnosed types of cancer. Pentacyclic triterpenoids are a group of plant compounds commonly known in traditional medicine due to their anti-inflammatory, antibacterial, antidiabetic, cardioprotective and anticancer effects. This review examined the potential of pentacyclic triterpenoid acids in the treatment of breast cancer, focusing on research from the past 15 years. Although the subject literature demonstrates that pentacyclic acids show anticancer activity, it also reveals their limitations such as low bioavailability, aqueous solubility, or high IC

Indexed as

Antineoplastic AgentsAntineoplastic Agents, PhytogenicBreast NeoplasmsPentacyclic TriterpenesFemaleHumansLupanesOleanolic AcidTriterpenesAntineoplastic AgentsAntineoplastic Agents, PhytogenicLupanesOleanolic AcidPentacyclic TriterpenesTriterpenesanticancerbreast cancerpentacyclic triterpenoids

Identifiers

PMID42796494
PMCPMC13609783

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.